Cryoport, Inc. experienced a steep revenue decline of nearly 23% in FY2025 after years of rapid growth but achieved a notable swing to positive net income, supported by substantial operating loss reduction. The company executed a focused divestiture strategy to sharpen its core Life Sciences Services and Products offerings, particularly targeting cell and gene therapy logistics, while managing large international regulatory and operational challenges. Capital allocation has favored share repurchases and debt reduction amid ongoing investments in cryogenic infrastructure crucial for cold chain integrity. Key metrics to monitor include customer concentration shifts, clinical trial demand, pricing dynamics, and capital structure adjustments.